Anaphylaxis

Anaphylaxis and anaphylactoid reactions are life-threatening events. A significant portion of the U.S. population is at risk for these rare but deadly events which cause approximately 1,500 deaths annually. (1) Anaphylaxis is mediated by immunoglobulin E (IgE), while anaphylactoid reactions are not. Both lead to the release of mast cell and basophil immune mediators (Table 1). Because of their clinical similarities, the term anaphylaxis will be used to refer to both conditions.

Clinical Presentation

Anaphylaxis may include any combination of common signs and symptoms (Table 2). (2)

Cutaneous manifestations of anaphylaxis, including urticaria and angioedema, are by far the most common. (3,4) The respiratory system is commonly involved, producing symptoms such as dyspnea, wheezing, and upper airway obstruction from edema. Gastrointestinal manifestations (e.g., nausea, vomiting, diarrhea, abdominal pain) and cardiovascular manifestations (e.g., dizziness, syncope, hypotension) affect about one third of patients. Headache, rhinitis, substernal pain, pruritus, and seizure occur less frequently.

Symptom onset varies widely but generally occurs within seconds or minutes of exposure. Rarely, anaphylaxis may be delayed for several hours. Anaphylaxis can be protracted, lasting for more than 24 hours, or recur after initial resolution. (5,6)

Etiology

The common etiologies of anaphylaxis include drugs, foods, insect stings, and physical factors/exercise (Table 3). (2) Idiopathic anaphylaxis (or reacting where no cause is identified) accounts for up to two thirds of persons who present to an allergist/immunologist.

Approximately one third of anaphylactic episodes are triggered by foods such as shellfish, peanuts, eggs, fish, milk, and tree nuts (e.g., almonds, hazelnuts, walnuts, pecans); however, the true incidence is probably underestimated. A patient may underestimate the importance of a food antigen, or the antigen may be one of many ingredients in a complex product. Some persons may react just by handling the culprit food.

Another common cause of anaphylaxis is a sting from a fire ant or Hymenoptera (bee, wasp, hornet, yellow jacket, and sawfly). Approximately 40 to 100 deaths per year in the United States result from insect stings, and up to 3 percent of the U.S. population may be sensitized. (1,2) A history of systemic reaction to an insect sting and positive venom skin test confers a 50 to 60 percent risk of reaction to future stings. (7)

Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) may produce a range of reactions, including asthma, urticaria, angioedema, and anaphylactoid reactions. "Aspirin sensitivity" affects about 10 percent of persons with asthma, particularly those who also have nasal polyps. Overall, aspirin accounts for an estimated 3 percent of anaphylactic reactions. (8) Symptoms may start immediately or several hours after ingestion. Sensitive persons may have similar reactions to NSAIDs antigenically unrelated to aspirin and must take only acetaminophen for mild pain or fever.

At one time penicillin was probably the most common cause of anaphylaxis. Between one and five per 10,000 patient courses with penicillin result in allergic reactions, with one in 50,000 to one in 100,000 courses having a fatal outcome, accounting for 75 percent of anaphylactic deaths in the United States. (9-11)

Latex allergy has become a significant problem since the widespread adoption of universal precautions against infection. Eight to 17 percent of health care workers experience some form of allergic reaction to latex, although not all of these reactions are anaphylaxis. (12) Recognizing latex allergy is critical because physicians may inadvertently expose the patient to more latex during treatment. Latex is in gloves, catheters, and countless other medical supplies, as well as thousands of consumer products. Persons allergic to latex also may be sensitive to fruits such as bananas, kiwis, pears, pineapples, grapes, and papayas.

Finally, radiographic contrast media can result in severe adverse reactions at a rate of 0.2 percent for ionic agents and 0.04 percent for lower osmolality, nonionic agents. (13) One study found the risk of death to be one in 100,000 with either type of agent. (14)

Differential Diagnosis

When history of exposure to an offending agent is elicited, the diagnosis of anaphylaxis is often obvious. Cutaneous manifestations of urticaria, itching, and angioedema assist in the diagnosis by suggesting an allergic reaction. However, when gastrointestinal symptoms predominate or cardiopulmonary collapse makes obtaining a history impossible, anaphylaxis may be confused with other entities. Some of these differential diagnoses are listed in Table 4.

If the diagnosis of anaphylaxis is not clear, laboratory evaluation can include plasma histamine levels, which rise as soon as five to 10 minutes after onset but remain elevated for only 30 to 60 minutes. Urinary histamine levels remain elevated somewhat longer. Alternatively, serum tryptase levels peak 60 to 90 minutes after onset of anaphylaxis and remain elevated for up to five hours. Some patients have isolated abnormal tryptase or histamine levels without the other.

Emergency Management

The initial management of anaphylaxis includes a focused examination, procurement of a stable airway and intravenous access, and administration of epinephrine. (2,10) [Evidence level C, consensus and expert opinion] Vital signs and level of consciousness should be documented. Examination may reveal urticaria, angioedema, wheezing, or laryngeal edema. If the antigen was injected (e.g., insect sting), the portal of entry may be noted.

Epinephrine 1:1,000 dilution, 0.2 to 0.5 mL (0.2 to 0.5 mg) in adults, or 0.01 mg per kg in children, should be injected subcutaneously or intramuscularly, usually into the upper arm. The site may be gently massaged to facilitate absorption. The dose may be repeated two or three times at 10 to 15 minutes intervals. If severe hypotension is present, epinephrine may be given as a continuous intravenous infusion. The following regimen is reasonable: 1:10,000 (10 mcg per mL) epinephrine at 1 mcg per minute, increased to 10 mcg per minute as needed. Patients receiving intravenous epinephrine require cardiac monitoring because of potential arrhythmias and ischemia. If an intravenous line cannot be established, the intramuscular dose can be injected into the posterior one third of the sublingual area, or the intravenous dose may be injected into an endotracheal tube.

The patient should be placed supine or in Trendelenburg's position. Supplemental oxygen may be administered. Intravenous access should be obtained for fluid resuscitation, because large volumes of fluids may be required to treat hypotension caused by increased vascular permeability and vasodilation. While volume replacement is central to management of hypotension in anaphylaxis, other pressors such as dopamine (Intropin), 2 to 20 mcg per kg per minute, may be required.

At this point, the patient should be assessed for response to treatment. Additional measures then may be individualized. (2,10) [Evidence level C, consensus and expert opinion] To slow absorption of injected antigens (e.g., insect stings), a tourniquet may be placed proximal to the injection site. It should be released every five minutes for at least three minutes, and the total duration of tourniquet application should not exceed 30 minutes. The tourniquet pressure should ideally occlude venous return without compromising arterial flow. Alternatively, 0.15 to 0.3 mL of 1:1,000 aqueous epinephrine (0.1 to 0.2 mL in children) may be injected into the site.

Persistent respiratory distress or wheezing requires additional measures. Nebulized beta-adrenergic agents such as albuterol (Proventil) may be administered, and intravenous aminophylline may be considered. Endotracheal intubation may be needed to secure the airway. Rarely, airway edema prevents endotracheal intubation and a surgical airway (e.g., emergency tracheostomy) is needed.

Antihistamines sometimes provide dramatic relief of symptoms. Simultaneous [H.sub.1] and [H.sub.2] blockade may be superior to [H.sub.1] blockade alone, so diphenhydramine (Benadryl), 1 to 2 mg per kg (maximum 50 mg) intravenously or intramuscularly, may be used in conjunction with ranitidine (Zantac), 1 mg per kg intravenously, or cimetidine (Tagamet), 4 mg per kg intravenously.

Although the exact benefit of corticosteroids has not been established, most experts advocate their administration. Their benefit is not realized for six to 12 hours after administration, so their primary role may be in prevention of recurrent or protracted anaphylaxis. There is no established drug or dosage of choice; Table 510 lists several possible regimens.

Patients taking beta-adrenergic blockers present a special challenge because beta blockade may limit the effectiveness of epinephrine. These patients may have resistant severe hypotension, bradycardia, and a prolonged course. Atropine may be given for bradycardia (0.3 to 0.5 mg intramuscularly or subcutaneously every 10 minutes to a maximum of 2 mg). Glucagon exerts positive inotropic and chronotropic effects on the heart, independent of catecholamines. Therefore, glucagon, 1 mg intravenous bolus, followed by an infusion of 1 to 5 mg per hour, may improve hypotension in one to five minutes, with a maximal benefit at five to 15 minutes. (The U.S. Food and Drug Administration has not approved glucagon for this use.) Nausea and vomiting may limit therapy with glucagon.

All patients with anaphylaxis should be monitored for the possibility of recurrent symptoms after initial resolution. (5,6) An observation period of two to six hours after mild episodes, and 24 hours after more severe episodes, seems prudent. Laboratory testing may help if the diagnosis of anaphylaxis is uncertain.

At discharge, the patient should be told to return for any recurrent symptoms. Some experts advocate a short course of antihistamines with oral corticosteroids (e.g., 30 to 60 mg of prednisone). (2,15)

Management of the Patient with a History of Anaphylaxis

A patient with a history of anaphylaxis should be instructed on how to initiate treatment for future episodes using pre-loaded epinephrine syringes. Two strengths are available: 0.3 mL of 1:1,000 epinephrine for adults, and 0.3 mL of 1:2,000 for children. Training kits containing empty syringes are available for patient education. Family members and caregivers of young children should be trained to inject epinephrine. Written instructions should be given. The patient also may take an antihistamine at the onset of symptoms. The patient must be told to seek immediate professional help regardless of initial response to self-treatment. If possible, the patient should avoid taking beta blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin-II receptor blockers, and monoamine oxidase inhibitors, because these drugs may interfere with successful treatment of future anaphylactic episodes or with the endogenous compensatory responses to hypotension. Finally, the patient should be advised to wear or carry a medical alert bracelet, necklace, or keychain to inform emergency personnel of the possibility of anaphylaxis.

Prevention of future episodes is vital (Table 6). This requires identification of the anaphylactic trigger, which is often difficult. The physician's primary tool is a detailed history of recent exposures to foods, medications, latex, and insects known to cause anaphylaxis. Previous tolerance of a substance does not rule it out as the trigger. Despite a detailed history, a cause remains elusive in many patients. Direct skin testing and radioallergosorbent testing (RAST) are available for some antigens, including heterologous sera, Hymenoptera venom, some foods, hormones, and penicillin. Skin testing itself carries a risk of fatal anaphylaxis and should be performed by experienced persons only. Scratch and prick tests should precede intradermal testing to decrease the risk of an unexpected severe reaction. Penicillin skin testing includes major and minor determinants; the minor determinants are more predictive of future anaphylactic events. RAST checks in vitro for the presence of IgE to antigen and carries no risk of anaphylaxis. However, it is limited to the same antigens that are available for skin testing. Both skin testing and RAST have imperfect sensitivity and specificity.

When there is no choice but to re-expose the patient to the anaphylactic trigger, desensitization or pretreatment may be attempted. Desensitization carries a risk of anaphylaxis and should be performed by experienced persons in a well-equipped location. In this procedure, the patient is exposed to gradually increasing amounts of antigen, usually via intradermal, then subcutaneous, then intravenous routes. Immunotherapy is recommended for insect sting anaphylaxis, because it is 97 percent effective at preventing recurrent severe reactions. (16) Protocols are available for oral and parenteral desensitization to penicillin, as well as a number of other antibiotics and medications. (17,18) Desensitization must be repeated if treatment with the agent is interrupted.

In situations where desensitization is not possible, pretreatment with steroids and antihistamines is an option. For a sensitive patient urgently requiring radiocontrast, 50 mg of oral prednisone 13 hours, seven hours, and one hour before contrast plus 50 mg of diphenhydramine one hour before the procedure dramatically reduce the rate of recurrent reaction. (19) Some experts advocate the addition of 25 mg of ephedrine, and 300 mg of cimetidine orally one hour before the procedure. (20) If the patient cannot take oral medications, 200 mg of hydrocortisone intravenously may replace prednisone in these regimens. The use of nonionic contrast media provides additional protection. (13)

Consultation with an allergist can help (1) confirm the diagnosis of anaphylaxis; (2) identify the anaphylactic trigger through history, skin testing, and RAST; (3) educate the patient in the prevention and initial treatment of future episodes; and (4) aid in desensitization and pretreatment when indicated.

The author indicates that she does not have any conflicts of interest. Sources of funding: none reported.

REFERENCES

(1.) Neugut AI, Ghatak AT, Miller RL. Anaphylaxis in the United States: an investigation into its epidemiology. Arch Intern Med 2001;161:15-21.

(2.) Lieberman P. Anaphylaxis and anaphylactoid reactions. In: Middleton E. Allergy: principles and practice. 5th ed. St. Louis: Mosby, 1998:1079-89.

(3.) University of Maryland Web site. Retrieved March 18, 2002, from umm.drkoop.com/conditions/ency/ images/fullsize/2313.jpg.

(4.) Dermatologic terminology. Retrieved July 23, 2003, from http://sprojects.mmi.mcgill.ca/dermatology /terminology.htm.

(5.) Stark BJ, Sullivan TJ. Biphasic and protracted anaphylaxis. J Allergy Clin Immunol 1986;78(1 Pt 1): 76-83.

(6.) Brady WJ Jr, Luber S, Carter CT, Guertler A, Lindbeck G. Multiphasic anaphylaxis: an uncommon event in the emergency department. Acad Emerg Med 1997;4(3):193-7.

(7.) Graham DM, McPherson H, Lieberman P. Skin testing in the evaluation of hymenoptera allergy and drug allergy. Immunol Allergy Clin North Am 2001; 21(2):301-20.

(8.) Kemp SF, Lockey RF, Wolf BL, Lieberman P. Anaphylaxis. A review of 266 cases. Arch Intern Med 1995;155:1749-54.

(9.) Idsoe O, Guthe T, Willcox RR, de Weck AL. Nature and extent of penicillin side-reactions, with particular reference to fatalities from anaphylactic shock. Bull World Health Organ 1968;38:159-88.

(10.) Joint Task Force on Practice Parameters. The diagnosis and management of anaphylaxis. J Allergy Clin Immunol 1998;101(6 Pt 2):S465-528.

(11.) Delage C, Irey NS. Anaphylactic deaths: the clinicopathologic study of 43 cases. J Forensic Sci 1972; 17:525-40.

(12.) Latex Hypersensitivity Committee of the American College of Allergy, Asthma, and Immunology. Latex allergy--an emerging healthcare problem. Ann Allergy Asthma Immunol 1995;75:19-21.

(13.) Katayama H, Yamaguchi K, Kozuka T, Takashima T, Seez P, Matsuura K. Adverse reactions to ionic and nonionic contrast media. A report from the Japanese Committee on Safety of Contrast Media. Radiology 1990;175:621-8.

(14.) Caro JJ, Trindade E, McGregor M. The risks of death and severe nonfatal reactions with high- vs low-osmolality contrast media: a meta-analysis. Am J Roentgenol 1990;156:825-32.

(15.) McGrath KG. Anaphylaxis. In: Patterson R. Allergic diseases: diagnosis and management. 4th ed. Philadelphia: J.B. Lippincott, 1993:587-610.

(16.) Portnoy JM, Moffitt JE, Golden DB, Bernstein WE, Dykewics MS, Fineman SM, et al. Stinging insect hypersensitivity: a practice parameter. J Allergy Clin Immunol 1999;103(5 Pt 1):963-80.

(17.) Weiss ME, Adkinson NF. Beta-lactam allergy. In: Mandell GL, Douglas RG, Bennett JE, Dolin, R. Mandell, Douglas, and Bennett's Principles and practice of infectious diseases. 5th ed. Philadelphia: Churchill Livingstone, 2000:304.

(18.) Gruchalla RS. Acute drug desensitization. Clin Exp Allergy 1998;28(Suppl 4):63-4.

(19.) Greenberger PA, Patterson R. The prevention of immediate generalized reactions to radiocontrast media in high-risk patients. J Allergy Clin Immunol 1991;87:867-72.

(20.) Marshall GD Jr, Lieberman PL. Comparison of three pretreatment protocols to prevent anaphylactoid reactions to radiocontrast media. Ann Allergy 1991;67:70-4.

ANGELA W. TANG, M.D., is an assistant clinical professor of internal medicine at the University of California, Los Angeles, UCLA School of Medicine and is on the academic faculty of the internal medicine residency program at St. Mary Medical Center, Long Beach, Calif. She received her medical degree from Columbia University College of Physicians and Surgeons, New York, and completed training in internal medicine at Harbor-UCLA Medical Center, Torrance, Calif., and a chief residency at St. Mary Medical Center.

Address correspondence to Angela W. Tang, M.D., Medical Education, St. Mary Medical Center, 1050 Linden Ave., Long Beach, CA 90813 (e-mail: atang@medicity.com). Reprints are not available from the author.

COPYRIGHT 2003 American Academy of Family Physicians
COPYRIGHT 2003 Gale Group